Dae Gon Ha
Stock Analyst at Stifel
(2.45)
# 2,427
Out of 5,182 analysts
55
Total ratings
37.78%
Success rate
4.22%
Average return
Main Sectors:
Stocks Rated by Dae Gon Ha
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| MIRM Mirum Pharmaceuticals | Maintains: Buy | $98 → $125 | $95.65 | +30.68% | 6 | Feb 26, 2026 | |
| ABEO Abeona Therapeutics | Maintains: Buy | $21 → $20 | $4.81 | +315.80% | 2 | May 16, 2025 | |
| EDIT Editas Medicine | Downgrades: Hold | $11 → $3 | $2.74 | +9.49% | 4 | Dec 13, 2024 | |
| SLNO Soleno Therapeutics | Maintains: Buy | $59 → $74 | $52.35 | +41.36% | 2 | Oct 1, 2024 | |
| FULC Fulcrum Therapeutics | Downgrades: Hold | $22 → $3 | $7.83 | -61.69% | 4 | Sep 12, 2024 | |
| NTLA Intellia Therapeutics | Maintains: Buy | $80 → $64 | $13.55 | +372.32% | 2 | Sep 11, 2024 | |
| KRYS Krystal Biotech | Maintains: Buy | $204 → $220 | $263.99 | -16.66% | 4 | Sep 11, 2024 | |
| RARE Ultragenyx Pharmaceutical | Maintains: Buy | $124 → $127 | $23.15 | +448.60% | 2 | May 31, 2024 | |
| RCKT Rocket Pharmaceuticals | Reiterates: Buy | $48 | $3.48 | +1,279.31% | 4 | Sep 13, 2023 | |
| PRME Prime Medicine | Initiates: Buy | $18 | $3.41 | +427.86% | 1 | Apr 18, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $12 → $7 | $1.92 | +264.58% | 1 | Mar 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $86 → $52 | $10.20 | +409.80% | 7 | Aug 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $23 → $25 | $86.66 | -71.15% | 4 | Jun 17, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $12 → $16 | $14.47 | +10.57% | 3 | Nov 15, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $285 | $25.77 | +1,005.94% | 1 | Sep 7, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $20 | $1.70 | +1,076.47% | 1 | May 3, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $9.71 | - | 2 | Sep 8, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | n/a | $40.70 | - | 1 | Jun 17, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | n/a | $9.59 | - | 1 | Jun 17, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $12 | $0.97 | +1,140.69% | 1 | Jun 17, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $600 → $490 | $20.75 | +2,261.45% | 2 | Oct 23, 2017 |
Mirum Pharmaceuticals
Feb 26, 2026
Maintains: Buy
Price Target: $98 → $125
Current: $95.65
Upside: +30.68%
Abeona Therapeutics
May 16, 2025
Maintains: Buy
Price Target: $21 → $20
Current: $4.81
Upside: +315.80%
Editas Medicine
Dec 13, 2024
Downgrades: Hold
Price Target: $11 → $3
Current: $2.74
Upside: +9.49%
Soleno Therapeutics
Oct 1, 2024
Maintains: Buy
Price Target: $59 → $74
Current: $52.35
Upside: +41.36%
Fulcrum Therapeutics
Sep 12, 2024
Downgrades: Hold
Price Target: $22 → $3
Current: $7.83
Upside: -61.69%
Intellia Therapeutics
Sep 11, 2024
Maintains: Buy
Price Target: $80 → $64
Current: $13.55
Upside: +372.32%
Krystal Biotech
Sep 11, 2024
Maintains: Buy
Price Target: $204 → $220
Current: $263.99
Upside: -16.66%
Ultragenyx Pharmaceutical
May 31, 2024
Maintains: Buy
Price Target: $124 → $127
Current: $23.15
Upside: +448.60%
Rocket Pharmaceuticals
Sep 13, 2023
Reiterates: Buy
Price Target: $48
Current: $3.48
Upside: +1,279.31%
Prime Medicine
Apr 18, 2023
Initiates: Buy
Price Target: $18
Current: $3.41
Upside: +427.86%
Mar 24, 2023
Maintains: Buy
Price Target: $12 → $7
Current: $1.92
Upside: +264.58%
Aug 10, 2022
Downgrades: Hold
Price Target: $86 → $52
Current: $10.20
Upside: +409.80%
Jun 17, 2022
Maintains: Buy
Price Target: $23 → $25
Current: $86.66
Upside: -71.15%
Nov 15, 2021
Upgrades: Buy
Price Target: $12 → $16
Current: $14.47
Upside: +10.57%
Sep 7, 2021
Initiates: Buy
Price Target: $285
Current: $25.77
Upside: +1,005.94%
May 3, 2021
Initiates: Buy
Price Target: $20
Current: $1.70
Upside: +1,076.47%
Sep 8, 2020
Downgrades: Neutral
Price Target: n/a
Current: $9.71
Upside: -
Jun 17, 2020
Initiates: Neutral
Price Target: n/a
Current: $40.70
Upside: -
Jun 17, 2020
Initiates: Neutral
Price Target: n/a
Current: $9.59
Upside: -
Jun 17, 2020
Initiates: Buy
Price Target: $12
Current: $0.97
Upside: +1,140.69%
Oct 23, 2017
Maintains: Outperform
Price Target: $600 → $490
Current: $20.75
Upside: +2,261.45%